An exciting new oral agent has recently become available to treat patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior chemotherapy containing docetaxel.
Abiraterone is an androgen biosynthesis inhibitor which acts at 3 sources of testosterone production: the testes, adrenal glands and prostate tumor tissue.
Hopefully, the indications for this once daily 250mg tablet will be expanded to include other patients who never received chemotherapy.
